CAMBRIDGE, Mass., April 21 /PRNewswire-FirstCall/ -- Transkaryotic
Therapies, Inc. (Nasdaq: TKTX) will report first quarter 2004 financial
results on Tuesday, April 27, 2004 before the open of U.S. financial markets.
In connection with this announcement, TKT will host a conference call and live
audio webcast on April 27, 2004 at 10:00 a.m. Eastern Time. Participants may
access the call by dialing (973) 317-5319. This call will also be broadcast
live over the Internet at http://www.tktx.com under the Investor Information section.
A replay of this conference call will be available for two weeks,
beginning Tuesday, April 27, 2004 at 1:00 p.m. Eastern Time by dialing (973)
709-2089 and using the access code 350896. In addition, a replay of the
webcast will be archived on the TKT website in the Investor Information
section.
About TKT
Transkaryotic Therapies, Inc. is a biopharmaceutical company primarily
focused on researching, developing and commercializing treatments for rare
diseases caused by protein deficiencies. Within this focus, the company
markets Replagal(TM), an enzyme replacement therapy for Fabry disease, and is
developing treatments for Hunter syndrome and Gaucher disease. Outside its
focus on rare diseases, TKT intends to commercialize Dynepo(TM), its Gene-
Activated(R) erythropoietin product for anemia related to kidney disease,
outside of the United States. TKT was founded in 1988 and is headquartered in
Cambridge, Massachusetts, with additional operations in Europe, Canada and
Latin America. Additional information about TKT is available on the
company's website at http://www.tktx.com.
Gene-Activated(R) is a registered trademark and Replagal(TM) is a
trademark of Transkaryotic Therapies, Inc. Dynepo(TM) is a trademark of
Aventis Pharmaceuticals, Inc.
CONTACT:
Daniella M. Lutz
Corporate Communications Specialist
(617) 349-0205
SOURCE Transkaryotic Therapies, Inc.
 back to top
Related links:
http://www.tktx.com
Photo Notes:
NewsCom:
http://www.newscom.com/cgi-bin/prnh/19990913/TKTLOGO
AP Archive: http://photoarchive.ap.org
PRN Photo Desk, 888-776-6555 or 212-782-2840
Company News On-Call:
http://www.prnewswire.com/comp/120657.html
CONTACT:
Daniella M. Lutz, Corporate Communications
Specialist of Transkaryotic Therapies, Inc., +1-617-349-0205
|
